CVS Health (CVS) has drawn fresh attention after launching a GLP-1 weight loss program that combines virtual consultations with access to these medicines, prompting analysts to reassess the company’s earnings potential and managed care exposure.

At a share price of US$103.58, CVS Health has seen momentum build recently, with a 30 day share price return of 13.85% and a 90 day share price return of 44.22%. The 1 year total shareholder return of 55.65% sits against headlines ranging from the GLP 1 program launch to an Attorney General probe into its Caremark unit.

If this shift in sentiment around CVS Health has caught your eye, it could be a good moment to see how other healthcare related AI opportunities are trading using the 41 healthcare AI stocks

With CVS Health trading close to updated analyst targets and flagged as materially below some implied fair value estimates, the key question is whether recent GLP 1 optimism leaves upside on the table or whether the stock already reflects future growth.

Most Popular Narrative: 40% Undervalued

According to a widely followed narrative from user yiannisz, CVS Health's fair value of about $104 sits well above the last close of $103.58, framing the recent share price run against a still discounted long term story.

CVS Health’s recent stock drop reveals a deeply undervalued healthcare giant with strong upside potential if its $2 billion restructuring plan succeeds in boosting profitability and stabilizing growth.

Curious what sits behind that fair value for CVS Health? The narrative leans on a detailed cash flow path, tighter costs, and a reworked earnings profile that assumes the healthcare platform shift really takes hold over time.

Result: Fair Value of $104.01 (UNDERVALUED)

However, CVS Health still faces real pressure from higher medical costs in its Health Care Benefits segment and ongoing regulatory scrutiny. Either of these factors could weaken this undervaluation thesis.

Another View: CVS Health Looks Expensive On Earnings

While one narrative sees CVS Health as deeply undervalued, the current P/E of 45.1x tells a different story. That multiple sits above the US Healthcare industry at 25.1x, above peers at 19.5x, and above a fair ratio of 37.7x. This points to valuation risk if earnings disappoint.

For investors comparing these signals, the key question is whether the premium is just a short term stretch or a sign the market is already pricing in a lot of good news for CVS Health.

Next Steps

If the mix of enthusiasm and caution around CVS Health has you undecided, it makes sense to act promptly and review the numbers for yourself, weighing the 2 key rewards and 5 important warning signs

Looking for more investment ideas beyond CVS Health?

If CVS Health has sharpened your focus on healthcare, do not stop there. Broaden your watchlist with other opportunities that fit different goals and risk levels.

• Target higher income potential by scanning companies in the 9 dividend fortresses that combine meaningful yields with resilient business profiles.
• Strengthen your downside protection by reviewing the 70 resilient stocks with low risk scores to see which stocks score well on resilience and risk controls.
• Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems and see which under-the-radar stocks could deserve a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.